Glanbia (GL9) Q1 2025 earnings summary

Executive summary

• Group revenue increased by 7.2% year-over-year, with growth driven by Health & Nutrition and Dairy Nutrition, and 2.7% contributed by acquisitions, despite Performance Nutrition declines in the US club and specialty channels.

• Transformation program advanced, focusing on efficiency, operating model changes, portfolio optimization, and non-core business exits, with a target of at least €50 million annual cost savings by 2027.

• Q1 2025 performance met expectations, with strong demand for nutrition brands and progress on cost inflation mitigation.

Financial highlights

• Net debt at quarter-end was $578.8 million, with committed facilities of $1.3 billion and average maturity of 3.5 years.

• Capital expenditure for the year expected between $80 million and $90 million, focused on capacity, integration, and IT.

• €50 million share buyback ongoing, with €42.7 million repurchased and canceled; additional €100 million buyback authority approved, pending annual meeting.

Outlook and guidance

• Full-year adjusted EPS guidance reiterated at $1.24–$1.30, with performance weighted to the second half.

• Performance Nutrition like-for-like revenue (excluding SlimFast and Body & Fit) expected to be broadly in line with 2024; EBITDA margin guidance at 13–14%.

• Health & Nutrition expected to deliver mid-single-digit like-for-like revenue growth, predominantly volume-led, and EBITDA margins of 17–18%.

• Dairy Nutrition profitability growth expected to continue, with strong Q1 momentum.

• Operating cash flow conversion expected to exceed 80% for the year.